Fierce Biotech February 21, 2024
In much the same way that Cagent Vascular’s flagship device is designed to help open up blocked arteries to promote blood flow, a recent round of funding for the startup is now slated to widen the device’s path in the commercial market.
The series C round brought in $30 million for Cagent, according to its announcement Tuesday. U.S. Venture Partners let the financing, with additional help from Blue Ridge Medical and Sectoral Asset Management, among other backers.
The round more than triples Cagent’s last fundraising, which closed with $9M from Sectoral Asset Management in mid-2021.
“This infusion of capital will increase our commercial reach, helping to provide greater access for healthcare providers and their patients,” CEO Carol Burns said in...
Today's Sponsors
Today's Sponsor